杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/12/07 | 1,836 | 1,848 | 1,827 | 1,835 | -18 | -1% | 52,100 |
2023/12/06 | 1,837 | 1,858 | 1,833 | 1,853 | +21 | +1.1% | 97,000 |
2023/12/05 | 1,827 | 1,848 | 1,823 | 1,832 | -2 | -0.1% | 68,200 |
2023/12/04 | 1,831 | 1,838 | 1,811 | 1,834 | -16 | -0.9% | 65,000 |
2023/12/01 | 1,828 | 1,850 | 1,828 | 1,850 | +22 | +1.2% | 99,500 |
2023/11/30 | 1,823 | 1,831 | 1,810 | 1,828 | +5 | +0.3% | 167,800 |
2023/11/29 | 1,837 | 1,839 | 1,822 | 1,823 | -14 | -0.8% | 61,600 |
2023/11/28 | 1,811 | 1,839 | 1,797 | 1,837 | +34 | +1.9% | 107,400 |
2023/11/27 | 1,823 | 1,823 | 1,794 | 1,803 | -12 | -0.7% | 73,000 |
2023/11/24 | 1,820 | 1,830 | 1,813 | 1,815 | +1 | +0.1% | 77,800 |
2023/11/22 | 1,787 | 1,814 | 1,787 | 1,814 | +37 | +2.1% | 93,700 |
2023/11/21 | 1,785 | 1,787 | 1,769 | 1,777 | -12 | -0.7% | 59,400 |
2023/11/20 | 1,817 | 1,817 | 1,787 | 1,789 | -29 | -1.6% | 85,500 |
2023/11/17 | 1,770 | 1,818 | 1,770 | 1,818 | +44 | +2.5% | 114,500 |
2023/11/16 | 1,804 | 1,810 | 1,772 | 1,774 | -31 | -1.7% | 90,700 |
2023/11/15 | 1,816 | 1,821 | 1,791 | 1,805 | +6 | +0.3% | 72,800 |
2023/11/14 | 1,806 | 1,810 | 1,797 | 1,799 | +2 | +0.1% | 54,600 |
2023/11/13 | 1,816 | 1,817 | 1,786 | 1,797 | -23 | -1.3% | 72,800 |
2023/11/10 | 1,786 | 1,821 | 1,770 | 1,820 | +23 | +1.3% | 124,500 |
2023/11/09 | 1,806 | 1,806 | 1,786 | 1,797 | -19 | -1% | 125,000 |
2023/11/08 | 1,827 | 1,829 | 1,796 | 1,816 | -2 | -0.1% | 91,000 |
2023/11/07 | 1,804 | 1,826 | 1,798 | 1,818 | +18 | +1% | 80,200 |
2023/11/06 | 1,820 | 1,821 | 1,800 | 1,800 | -7 | -0.4% | 89,200 |
2023/11/02 | 1,804 | 1,810 | 1,793 | 1,807 | +12 | +0.7% | 81,700 |
2023/11/01 | 1,793 | 1,800 | 1,780 | 1,795 | +17 | +1% | 107,100 |
2023/10/31 | 1,735 | 1,779 | 1,735 | 1,778 | +44 | +2.5% | 116,900 |
2023/10/30 | 1,758 | 1,758 | 1,728 | 1,734 | -40 | -2.3% | 102,200 |
2023/10/27 | 1,754 | 1,774 | 1,743 | 1,774 | +21 | +1.2% | 92,600 |
2023/10/26 | 1,768 | 1,783 | 1,749 | 1,753 | -15 | -0.8% | 108,500 |
2023/10/25 | 1,795 | 1,795 | 1,768 | 1,768 | -14 | -0.8% | 108,200 |
2023/10/24 | 1,781 | 1,785 | 1,758 | 1,782 | -6 | -0.3% | 78,800 |
2023/10/23 | 1,785 | 1,800 | 1,777 | 1,788 | +3 | +0.2% | 58,300 |
2023/10/20 | 1,791 | 1,797 | 1,772 | 1,785 | -8 | -0.4% | 56,900 |
2023/10/19 | 1,778 | 1,803 | 1,778 | 1,793 | +4 | +0.2% | 66,100 |
2023/10/18 | 1,787 | 1,796 | 1,767 | 1,789 | +2 | +0.1% | 90,600 |
2023/10/17 | 1,782 | 1,793 | 1,775 | 1,787 | +5 | +0.3% | 52,000 |
2023/10/16 | 1,808 | 1,810 | 1,781 | 1,782 | -24 | -1.3% | 43,600 |
2023/10/13 | 1,819 | 1,833 | 1,798 | 1,806 | -28 | -1.5% | 71,200 |
2023/10/12 | 1,840 | 1,840 | 1,820 | 1,834 | -6 | -0.3% | 55,600 |
2023/10/11 | 1,833 | 1,847 | 1,822 | 1,840 | +9 | +0.5% | 82,700 |
2023/10/10 | 1,800 | 1,834 | 1,800 | 1,831 | +19 | +1% | 79,400 |
2023/10/06 | 1,793 | 1,829 | 1,793 | 1,812 | +6 | +0.3% | 68,400 |
2023/10/05 | 1,780 | 1,809 | 1,777 | 1,806 | +15 | +0.8% | 85,100 |
2023/10/04 | 1,794 | 1,813 | 1,780 | 1,791 | -21 | -1.2% | 81,600 |
2023/10/03 | 1,821 | 1,836 | 1,812 | 1,812 | -2 | -0.1% | 89,300 |
2023/10/02 | 1,847 | 1,850 | 1,814 | 1,814 | -17 | -0.9% | 105,800 |
2023/09/29 | 1,855 | 1,858 | 1,817 | 1,831 | -22 | -1.2% | 87,000 |
2023/09/28 | 1,831 | 1,863 | 1,819 | 1,853 | -10 | -0.5% | 149,800 |
2023/09/27 | 1,833 | 1,864 | 1,819 | 1,863 | +28 | +1.5% | 122,100 |
2023/09/26 | 1,830 | 1,845 | 1,820 | 1,835 | +11 | +0.6% | 90,400 |
101~
150
件表示中 / 3451件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 182,200円 | +2.6% | +11.5% | 2.85% | 21.36倍 | 0.83倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
持田薬 | 321,500円 | -1.2% | -37.3% | 2.49% | 25.90倍 | 0.90倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
ジーエヌアイ | 239,400円 | +52.1% | +23.3% | 0.00% | 16.92倍 | 3.53倍 |
|
創薬ベンチャー。米国で人工骨も。中国の特発性肺線維症薬で高シェア、米中に研究開発機能 |
鳥居薬 | 403,500円 | +7.3% | +16.8% | 2.97% | 24.14倍 | 0.94倍 |
|
JT傘下。自社製品の腎・透析、アレルゲン等の開発強化。柱の抗HIV薬の販売権喪失が直撃 |
ゼリア新薬 | 210,900円 | +6.8% | +18.7% | 2.09% | 13.28倍 | 1.23倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
市場注目の銘柄
チャート関連のコラム